Investor Presentation for quarter 1 ended 30 June 2026

Date: 12 August 2026 The Secretary The Secretary BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1. G Block Dalal Street Bandra -Kurla Complex, Bandra (East) Mumbai - 400 001 Mumbai- 400 051 Scrip Code: 544293 Scrip Symbol : SURAKSHA Dear Sir / Ma’am, Reg: Disclosure under Regulation 30(6) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 Sub: Presentation to be made at the Analyst(s) / Investor(s) Meet/ Conference- Earnings Call Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated 06 August 2026 regarding schedule of Analyst(s)/ Investor(s) Meet /Conference i.e Earnings Call on Thursday, 13 August 2026 at 11:30 A.M. (IST), we are hereby enclosing a copy of Investor Presentation on the unaudited (standalone and consolidated) financial results of the Company for quarter ended 30 June 2026. The Investor Presentation will be exhibited at the aforesaid Earnings Call and the same will be made available on the website of the Company at www.surakshanet.com. Please note that the schedule of the aforesaid Earnings Call is subject to change. The changes might happen due to exigencies on the part of the Company/ Analyst(s)/ Investor(s). This may please be informed to all the concerned. For Suraksha Diagnostic Limited Ritu Mittal Joint Managing Director & CEO DIN: 00165886 Encl.: as above Suraksha Diagnostic Limited (Formerly known as Suraksha Diagnostic Private Limited) CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town, Kolkata-700 156, West Bengal, India E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750 SURAKSHA DIAGNOSTIC LIMITED Investor Presentation | Q1 FY27 Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Suraksha Diagnostic Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Suraksha Diagnostic Limited| Investor Presentation 2 Q1 FY27 RESULT HIGHLIGHTS Q1 FY27 Performance Financial Performance YoY Growth % 21% 28% 40% Revenue from Operations INR 876.5 Mn Revenue Growth % EBITDA Growth % PAT Growth % Key Metrics EBITDA | EBITDA Margin % INR 315.3 Mn | 36.0% Revenue per Patient EBITDA per Patient B2C Revenue % INR 2,321 INR 835 91% PAT | PAT Margin % Tests Performed Footfall Centres INR 128.5 Mn | 14.7% 2.10 Mn 0.38 Mn 72 Suraksha Diagnostic Limited| Investor Presentation 4 Management Commentary on Q1 FY27 Results “Suraksha has begun FY27 on a strong footing. We have delivered YoY growth of 21% with an EBIDTA margin of 36.0% and PAT of 14.7% in Q1 FY27. Network expansion continued through the quarter with one hub and three spoke centres commissioned during Q1 FY27, We have carried this momentum into the current quarter, adding two hubs and three spoke centres in July and August. We have also extended our footprint beyond West Bengal, commissioning a hub centre in neighbouring Jharkhand, with a hub in Tripura to follow shortly. Ritu Mittal, Suraksha Genomics has grown to ₹13.7 million in Q1 FY27, up 136% year-on- Joint Managing Director & CEO year with five consecutive quarters of sequential growth — a small base today, but one we expect to become a meaningful pillar of the business.” Suraksha Diagnostic Limited| Investor Presentation 5 Q1 FY27 Key Financial Performance Total Income (INR Mn) EBITDA (INR Mn) PAT (INR Mn) +21% +28% +40% 887 315 128 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Suraksha Diagnostic Limited| Investor Presentation 6 Q1 FY27 Key Operating Metrics Number of Centres Number of patients (Mn) Number of Tests (Mn) 72 0.38 2.10 68 1.97 1.92 0.34 58 0.30 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Revenue / Patient (INR) EBITDA / Patient (INR) 2,321 2,264 2,101 707 719 Q1 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q4 FY26 Q1 FY27 Suraksha Diagnostic Limited| Investor Presentation 77 Statement of Profit & Loss (Consolidated) Particulars (INR Mn) Q1 FY27 Q1 FY26 Y-o-Y Q4 FY26 Q-o-Q FY26 Revenue from Operations 876.45 725.86 814.12 3,104.14 Other Income 10.88 9.06 7.85 31.64 Total Revenue 887.33 734.92 20.7% 821.97 7.9% 3135.78 Cost of Material Consumed 99.95 87.51 101.58 364.75 Employee Benefit Expenses 144.1 127.75 136.70 532.55 Other Expenses 328.5 282.00 329.20 1248.22 Impairment Loss/(gain) -0.52 -8.90 2.94 4.68 EBITDA 315.3 246.56 27.9% 251.55 25.3% 985.58 EBITDA Margin (%) 36.0% 34.0% 30.9% 31.8% Depreciation 112.82 94.82 112.58 414.48 Finance Cost 37.22 27.05 39.16 125.52 Profit before Tax & Exceptional Item 165.26 124.69 32.5% 99.81 65.6% 445.58 Exceptional Item - 0.00 0.0 - Profit before Tax 165.26 124.69 32.5% 99.81 65.6% 445.58 Profit before Tax (%) 18.85% 17.2% 12.3% 14.4% Tax 36.81 32.94 38.22 131.54 Profit After Tax 128.45 91.75 40.0% 61.59 108.5% 314.04 PAT Margin (%) 14.7% 12.6% 7.6% 10.1% EPS 2.50 1.80 1.21 6.18 Suraksha Diagnostic Limited| Investor Presentation 8 IGAAP vs IND AS Q1 FY27 Ind AS PARTICULARS (INR Mn) Ind AS IGAAP Impact TOTAL INCOME 887.3 0.97 886.4 EBITDA 315.3 67.1 248.2 EBITDA MARGIN 36.0% 28.3% INTEREST + DEPRECIATION 150.0 83.7 66.4 PAT 128.4 - 145.0 PAT MARGIN 14.7% 16.5% Note: The key difference between Indian GAAP (IGAAP under AS 19) and Indian Accounting Standards (Ind AS 116) in the treatment of lease rent lies in balan [Showing first 8,000 characters — download PDF for full document]